X
    X
    X
    X

    Stemline Therapeutics, Inc IPO

    In January 2013, an Edwards Wildman team advised Stemline Therapeutics, Inc. on its Initial Public Offering. Trumpeted by the BioWorld headline "Stemline Therapeutics Is First Biotech IPO of 2013", the offering was well received by investors, soaring 15% on its first day of trading on the NASDAQ. The deal involved Edwards Wildman corporate, finance, insurance and intellectual property team members from Boston and Chicago.

    Explore Additional Topics

    Disclaimer

    Please understand that your communications with Locke Lord LLP through this website do not constitute or create an attorney-client relationship with Locke Lord LLP. Any information you send to Locke Lord LLP through this website is on a non-confidential and non-privileged basis. Therefore, do not send or include any information in your email that you consider to be confidential or privileged.